arrow
S

Steven M. Larson

Memorial Sloan Kettering Cancer Center
H指数:133
被引数:6.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Establishment of 68Ga-DOTA-Based Pretargeted Radioimmunodiagnosis

基于68Ga-DOTA的预靶向放射免疫诊断的建立

2026-05-180
OA
225Ac α-Pretargeted Radioimmunotherapy of Human Epidermal Growth Factor Receptor 2-Expressing Breast Cancer

<sup>225</sup> 靶向人表皮生长因子受体2表达型乳腺癌的α-预靶向放射免疫疗法

2025-11-011
PRE
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer

2025年美国甲状腺协会成人分化型甲状腺癌管理指南

Thyroid
IF6.7
2025-08-200
PRE
IL13Ra2-Targeting Antibodies for Immuno-PET in Solid Malignancies

IL13Ra2靶向抗体在实体恶性病变中的免疫正电子发射断层成像应用

2025-02-200
PRE
Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177 Lu-Labeled Radiohapten
2024-08-210
PRE
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs

在核肿瘤学的日常临床实践中实现放射性药物治疗的个体化剂量: 克服对肿瘤和关键器官的辐射吸收剂量的异质性

2023-09-152
OAAI
Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis
2023-06-2211
OA
The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients
2023-05-122
OAAI
Engineering CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications
2023-01-015
OAAI
Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
2022-11-1230
OAAI
Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis
2022-01-0710
OA